Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 27Breast Neoplasms 23Neoplasms 22Pancreatic Neoplasms 19Prostatic Neoplasms 17Glioma 17Glioblastoma 16Leukemia, Myeloid, Acute 15Recurrence 14Solid Tumor 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Non-Hodgkin 12Brain Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Lung Neoplasms 9Triple Negative Breast Neoplasms 8Lymphoma 8Hematologic Neoplasms 8Melanoma 7Lymphoma, B-Cell 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Advanced Solid Tumors 7Polycystic Ovary Syndrome 6Neoplasm Metastasis 6Head and Neck Neoplasms 6Carcinoma, Hepatocellular 6Stomach Neoplasms 5Myelodysplastic Syndromes 5Leukemia, Plasma Cell 5

Interventions

disitamab vedotin 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Recruiting × Ovarian Cancer Recurrent × Clear all
NCT06660511 2024-10-28

Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

Second Xiangya Hospital of Central South University

Phase EARLY_PHASE1 Recruiting
5 enrolled
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡